Medicare will start covering weight-loss drugs next month through a temporary program that lawmakers may struggle to cancel later. The news comes as Germany plans its own pricing rules for these medicines.

• •Medicare will start covering weight-loss drugs next month via a temporary program
• •Germany is planning its own pricing rules for weight-loss medicines

Medicare will start selling GLP-1 weight-loss drugs for $50 per month starting July 1 under a new temporary program. The article says this program may become permanent even though it's meant to be temporary.

• •Medicare will sell GLP-1 weight-loss drugs for $50 per month starting July 1
• •The program is described as temporary but may become permanent
• •Program is tied to Trump's obesity drug plan

• •Abridge inked deals with Nvidia and Lilly per STAT News headline.

More employers plan to stop paying for GLP-1 weight-loss drugs next year as more people use them. The article covers employer coverage decisions and mentions a Sanofi setback, but full details aren't available in this excerpt.

• •More employers plan to stop paying for GLP-1 weight-loss drugs next year
• •Drop in employer coverage linked to rising number of people using the drugs

AstraZeneca tested a pill form of GLP-1 (a weight-loss and diabetes drug) in mid-stage trials and saw promising results. The company doesn't yet know how well it works compared to other pill versions on the market.

• •AstraZeneca tested a pill form of GLP-1 in mid-stage trials for obesity and diabetes
• •Results described as promising based on trial data
• •Company has not compared its pill to other oral GLP-1 drugs on the market

Eli Lilly released new safety and side-effect data on retatrutide, its next-generation weight-loss drug. The data give doctors more details about how the drug works in patients.

• •Eli Lilly released new safety and side-effect data on retatrutide
• •Retatrutide is described as Lilly's next-generation weight-loss drug

Boehringer Ingelheim released Phase 3 trial results for survodutide, its obesity drug. The drug cut liver fat well but didn't reduce weight as much as some competitors, raising questions about how it will compete in the market.

• •Survodutide Phase 3 data showed strong liver fat reduction
• •Weight loss results appeared lower than some competing obesity drugs
• •Data described as potentially hurting survodutide's competitive position

Eli Lilly shared safety and tolerability data on retatrutide, its next-generation weight-loss drug, at the American Diabetes Association's annual meeting. The data shows how well the drug works and what side effects patients experienced during testing.

• •Lilly shared safety and tolerability data on retatrutide at the American Diabetes Association annual meeting
• •Retatrutide is Lilly's next-generation weight-loss drug

Pfizer showed new details from a midstage trial of its obesity drug berobenatide, which the company bought from Metsera. The drug appears to work when given once a month instead of more often.

• •Pfizer showed new details from a midstage trial of berobenatide
• •Pfizer bought berobenatide from Metsera
• •Drug appears to work when given once a month

Eli Lilly's retatrutide, a weight-loss drug that works three different ways in the body, helped people in a major trial lose about one-quarter of their body weight. This result may be stronger than what competitors like Novo Nordisk have shown with their own weight-loss drugs.

• •Retatrutide is described as a triple-acting obesity drug
• •Drug helped people lose about one-quarter of their body weight in Phase 3
• •Result described as potentially stronger than Novo Nordisk competitor drugs

Eli Lilly said its new obesity drug worked almost as well as weight-loss surgery in a late-stage trial. The company tested the drug on people struggling with weight to see if it could help them lose pounds.

• •Lilly reported a new obesity drug performed nearly as well as weight-loss surgery in a late-stage trial

Eli Lilly's retatrutide (a three-hormone weight-loss drug) helped patients lose as much weight as bariatric surgery in a trial. However, some patients quit the study because of side effects.

• •Retatrutide is a three-hormone weight-loss drug made by Eli Lilly
• •Trial results showed weight loss comparable to bariatric surgery
• •Some patients dropped out of the study due to side effects

Maryland's state drug board set a price cap on Ozempic (a weight-loss and diabetes drug made by Novo Nordisk). Nine states are trying similar rules to make expensive drugs cost less for patients.

• •Maryland state drug affordability board set a price cap on Ozempic
• •Nine states are pursuing similar drug price cap rules
• •Ozempic is made by Novo Nordisk

Eli Lilly's trial data suggests that people losing weight on high-dose shot versions of its drug could switch to lower doses or pills and still keep the weight off. The findings point to cheaper, easier ways to maintain weight loss once someone has hit their goal.

• •Lilly trial data suggest patients on high-dose injections may switch to lower doses or pills to maintain weight loss
• •Findings point to maintenance strategies after patients reach their weight-loss goal